Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 13, 2015 8:19 AM ET


Company Overview of Stellar Biotechnologies, Inc.

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. KLH is an immune-stimulating protein used for generation of antibody and cell-mediated immune responses against disease indications, such as cancer, immune disorders, Alzheimer’s, and inflammatory diseases, as well as used for therapeutic vaccine conjugation in immunotherapies. The company also offers in vitro diagnostic kits for preclinical use. It provides its products under the Stellar KLH brand name. The company serves multinational biotechnology and pha...

332 East Scott Street

Port Hueneme, CA 93041

United States

23 Employees





Key Executives for Stellar Biotechnologies, Inc.

Chairman, Chief Executive Officer and President
Age: 64
Total Annual Compensation: $402.3K
Chief Financial Officer and Corporate Secretary
Age: 57
Total Annual Compensation: $175.0K
Chief Operating Officer
Age: 41
Total Annual Compensation: $178.3K
Compensation as of Fiscal Year 2014.

Stellar Biotechnologies, Inc. Key Developments

Stellar Biotechnologies, Inc. and Amaran Biotechnology Inc. Provide Update on Collaboration

Stellar Biotechnologies, Inc. provided an update on the company's ongoing collaboration with Amaran Biotechnology, Inc. The alliance between Stellar and Amaran was formed in 2013 to develop and evaluate methods for the manufacture of the OBI-822 immunotherapy, which incorporates Stellar KLHTM as the immune-stimulating carrier molecule. Stellar and Amaran have now completed all primary objectives of the collaboration, which include method development, formulation, and process qualification for GMP-grade Stellar KLHTM and meeting the specifications needed for the production of OBI-822. The next stage of the collaboration will involve scale-up and optimization of processes to commercial manufacturing levels, with the focus on production, quality, and regulatory requirements to support OBI Pharma's planned global Phase III trial and potential future market launch.

Stellar Biotechnologies, Inc. Proposes Amendment to the By-Laws

Stellar Biotechnologies, Inc. proposed an amendment to the company's articles (by-laws) to amend certain corporate governance requirements in connection with the company's application for up-listing to The NASDAQ Capital Market (NASDAQ), at its special meeting of shareholders of the company will be held on October 29, 2015.

Stellar Biotechnologies, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015

Stellar Biotechnologies, Inc. announced consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported total revenue of USD 157,748, net income of USD 463,986 or USD 0.01 per basic and diluted share against the total revenue was USD 72,538, net income was USD 3,408,326 or USD 0.04 per basic and diluted share a year ago. Revenue was driven primarily by an increase in product sales period-over-period. The year-over-year decrease in net income was primarily due to fluctuations in noncash gains in the fair value of warrant liability, increased revenue and decreased research and development expenses. For the nine months, the company reported total revenue of USD 558,036, net loss of USD 1,305,655 or USD 0.02 per basic and diluted share against the total revenue was USD 245,734, net income was USD 3,602,718 or USD 0.05 per basic and diluted share a year ago. The period-over-period decrease in net loss was primarily due to significant noncash gains in the fair value of warrant liability, increased revenues and decreased research and development expenses, net of increased noncash foreign exchange loss. Net cash used in operating activities of USD 3,497,293 compared to USD 3,660,304 a year ago.

Similar Private Companies By Industry

Company Name Region
EnviroGro Solutions, Inc. United States
ArgentumCidalElectrics Inc. United States
Imstem Biotechnology, Inc. United States
Applied Microarrays, Inc. United States
Arkion Life Sciences, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Stellar Biotechnologies, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at